These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

105 related items for PubMed ID: 21091771

  • 1. Integrin β3 and its ligand regulate the expression of uPA through p38 MAPK in breast cancer.
    Wang R, Li ZQ, Han X, Li BL, Mi XY, Sun LM, Song M, Han YC, Zhao Y, Wang EH.
    APMIS; 2010 Dec; 118(12):909-17. PubMed ID: 21091771
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Urokinase plasminogen activator/urokinase-specific surface receptor expression and matrix invasion by breast cancer cells requires constitutive p38alpha mitogen-activated protein kinase activity.
    Huang S, New L, Pan Z, Han J, Nemerow GR.
    J Biol Chem; 2000 Apr 21; 275(16):12266-72. PubMed ID: 10766865
    [Abstract] [Full Text] [Related]

  • 4. Rac1-MKK3-p38-MAPKAPK2 pathway promotes urokinase plasminogen activator mRNA stability in invasive breast cancer cells.
    Han Q, Leng J, Bian D, Mahanivong C, Carpenter KA, Pan ZK, Han J, Huang S.
    J Biol Chem; 2002 Dec 13; 277(50):48379-85. PubMed ID: 12377770
    [Abstract] [Full Text] [Related]

  • 5. Alpha(v) integrin, p38 mitogen-activated protein kinase, and urokinase plasminogen activator are functionally linked in invasive breast cancer cells.
    Chen J, Baskerville C, Han Q, Pan ZK, Huang S.
    J Biol Chem; 2001 Dec 21; 276(51):47901-5. PubMed ID: 11606583
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Regulation by p38 mitogen-activated protein kinase of adenylate- and uridylate-rich element-mediated urokinase-type plasminogen activator (uPA) messenger RNA stability and uPA-dependent in vitro cell invasion.
    Montero L, Nagamine Y.
    Cancer Res; 1999 Oct 15; 59(20):5286-93. PubMed ID: 10537311
    [Abstract] [Full Text] [Related]

  • 8. Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors.
    Jahkola T, Toivonen T, von Smitten K, Virtanen I, Wasenius VM, Blomqvist C.
    Br J Cancer; 1999 Apr 15; 80(1-2):167-74. PubMed ID: 10389993
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Tenascin-C deposition requires beta3 integrin and Src.
    Yang Y, Dang D, Mogi S, Ramos DM.
    Biochem Biophys Res Commun; 2004 Sep 24; 322(3):935-42. PubMed ID: 15336554
    [Abstract] [Full Text] [Related]

  • 12. Stromal cell-derived factor-1 (SDF-1) enhances cells invasion by αvβ6 integrin-mediated signaling in ovarian cancer.
    Xue B, Wu W, Huang K, Xie T, Xu X, Zhang H, Qi C, Ge J, Yu Y.
    Mol Cell Biochem; 2013 Aug 24; 380(1-2):177-84. PubMed ID: 23615713
    [Abstract] [Full Text] [Related]

  • 13. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R, Schaaf A.
    Int J Oncol; 2009 Jan 24; 34(1):15-23. PubMed ID: 19082473
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Association between alphavbeta6 integrin expression, elevated p42/44 kDa MAPK, and plasminogen-dependent matrix degradation in ovarian cancer.
    Ahmed N, Pansino F, Baker M, Rice G, Quinn M.
    J Cell Biochem; 2002 Jan 24; 84(4):675-86. PubMed ID: 11835393
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Lysophosphatidic acid induction of urokinase plasminogen activator secretion requires activation of the p38MAPK pathway.
    Estrella VC, Eder AM, Liu S, Pustilnik TB, Tabassam FH, Claret FX, Gallick GE, Mills GB, Wiener JR.
    Int J Oncol; 2007 Aug 24; 31(2):441-9. PubMed ID: 17611702
    [Abstract] [Full Text] [Related]

  • 19. ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK).
    Aguirre-Ghiso JA, Estrada Y, Liu D, Ossowski L.
    Cancer Res; 2003 Apr 01; 63(7):1684-95. PubMed ID: 12670923
    [Abstract] [Full Text] [Related]

  • 20. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
    Han B, Nakamura M, Zhou G, Ishii A, Nakamura A, Bai Y, Mori I, Kakudo K.
    Int J Oncol; 2006 Apr 01; 28(4):807-14. PubMed ID: 16525628
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.